McKnight's April 17, 2024
Kristen Fischer

Older adults are not represented adequately in clinical trials of medications for disorders that are common in the population. The legal framework to better represent them is in place, but not enough is happening to increase the number of older adults involved in research, according to a paper published on April 10 in the Journal of the American Geriatrics Society.

“Without the enrollment of older adults that are representative of clinical populations in clinical trials, clinicians will continue to be faced with uncertainty as to the safety and efficacy of new drugs for older adults,” Janice B. Schwartz, MD, a professor of medicine at University of California San Francisco, wrote in the report.

A new law mandates that clinical trial...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Patient / Consumer, Trends
When Medical A.I. is Lifesaving
STAT+: Doctors Without Borders challenges pharma by releasing costs for a key clinical trial
Systems thinking: A new paradigm for clinical trial design and operations
Duchenne Muscular Dystrophy: the global clinical trials landscape 2024
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition

Share This Article